AVERY MONDAY
Fabrazyme patient
California, U.S.A.

Avery is just like many nine-year-olds. He loves animals, video games and sports. A Fabry patient herself, Avery's mother found out he had the disease through testing while pregnant. Avery and his grandfather-who also has Fabry-share an avid interest in raising bearded dragon lizards.

› CEREZYME^® / imiglucerase for injection
› FABRAZYME^® / agalsidase beta
› ALDURAZYME^® / laronidase
› MYOZYME^® / alglucosidase alfa

The Genetic Disease business is Genzyme's largest and most established, focused on four innovative enzyme replacement therapies for the treatment of lysosomal storage disorders (LSDs). This unit continues to grow, driven by strong treatment efficacy and safety, global expansion and an ongoing pursuit of innovation.

Myozyme is the first and only treatment available for patients with Pompe disease. After its highly successful launch in 2006, the newest and fastest growing of our life-saving therapies continued its momentum with approval and launch in Japan in record time in 2007 and strong growth in Europe. As of the end of the year, Myozyme was approved in 36 countries. In December, we announced that our post-marketing Late Onset Treatment Study (LOTS) for Myozyme met its co-primary endpoints, confirming the benefit of this important therapy for adults with Pompe disease.

Fabrazyme is Genzyme's market-leading therapy for patients with Fabry disease. With compelling clinical data and a strong global organization, Fabrazyme has proved to be an effective and widely accepted treatment, capturing two-thirds of the international market for Fabry disease.

We expect the business to benefit from full marketing approval received in the European Union for Fabrazyme in early 2008. We continue to invest to advance our ability to treat patients at the optimal time, launching an international clinical study to better understand Fabrazyme's effect in the early stages of Fabry disease.

Cerezyme, our treatment for Gaucher disease, now exceeds $1 billion in product revenues and is available in more than 90 countries. More than 15 years after the launch of Genzyme's first Gaucher therapy, Cerezyme is still growing because of its effectiveness at meeting patients' needs. In 2007, we completed enrollment of a phase 2 trial for small molecule Genz-112638, a novel oral therapy that could provide an additional treatment option for Gaucher patients. Initial results have been encouragingÑwe expect to present one-year data later in 2008.

Aldurazyme, the only approved therapy for patients with mucopolysaccharidosis Type I (MPS I), also delivered strong growth in 2007. In early 2008, we announced a restructuring of our joint venture relationship with BioMarin Pharmaceutical Inc. that better aligns incentives with our respective roles in producing and marketing the product.